KEYNOTE-667: PHASE 2 STUDY OF PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONTLINE CHEMOTHERAPY

被引：0

作者：

Vinti, Luciana ^{[1
]}

Daw, Stephen ^{[2
]}

Alvarez, Constantino Sabado ^{[3
]}

Fagioli, Franca ^{[4
]}

Beishuizen, Auke ^{[5
]}

Michel, Gerard ^{[6
]}

Moleti, Maria Luisa ^{[7
]}

Cepelova, Michaela ^{[8
]}

Thorwarth, Anne ^{[9
]}

Rigaud, Charlotte ^{[10
]}

De Sabando, Diego Plaza Lopez ^{[11
]}

Parker, Judith Landman ^{[12
]}

Zhu, Ying ^{[13
]}

Pillai, Pallavi ^{[13
]}

Nahar, Akash ^{[13
]}

Mauz-Koerholz, Christine ^{[14
,15
]}

机构：

[1] IRCCS Osped Pediatrico Bambino Gesu, Pediat Hematol & Oncol, Rome, Italy

[2] Univ Coll London Hosp NHS Fdn Trust, Pediat & Hematol Oncol, London, England

[3] Hosp Univ Vall Hebron, Pediat Oncol, Barcelona, Spain

[4] Osped Infantile Regina Margherita, Pathol & Child Care, Turin, Italy

[5] Princess Maxima Centrum, Hematol Malignancies, Utrecht, Netherlands

[6] CHU Marseille, Hop Timone Enfants, Pediat & Pediat Hematol, Marseille, France

[7] Univ Roma La Sapienza, Pediat Hematol & Oncol, Rome, Italy

[8] Fak Nemocnice Motole, Pediat Hematol & Oncol, Prague, Czech Republic

[9] Charite Univ Med Berlin, Campus Virchow Klinikum, Pediat Oncol & Hematol, Berlin, Germany

[10] Gustave Roussy Canc Campus, Pediat Hematol & Oncol, Villejuif, France

[11] Hosp Univ La Paz, Pediat Hematol & Oncol, Madrid, Spain

[12] Hop Enfants Armand Trousseau, Pediat, Paris, France

[13] Merck Co Inc, Med Oncol, Kenilworth, NJ USA

[14] Justus Liebig Univ Giessen, Giessen, Germany

[15] Martin Luther Univ Halle Wittenberg, Fac Med, Pediat Hematol & Oncol, Halle, Germany

来源：

PEDIATRIC BLOOD & CANCER | 2022年 / 69卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O046

引用

页数：2

共 50 条

[1] PHASE 2 KEYNOTE-667 STUDY OF PEMBROLIZUMAB (PEMBRO) IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA (Chl) AND SLOW EARLY RESPONSE (SER) TO FRONTLINE CHEMOTHERAPY (CHEMO)
Vinti, L.
Daw, Stephen
Alvarez, C.
Fagioli, F.
Beishuizen, A.
Michel, G.
Moleti, M.
Cepelova, M.
Thorwarth, A.
Rigaud, C.
de Sabando, D.
Parker, J.
Zhu, Y.
Pillai, P.
Nahar, A.
Mauz-Koerholz, C.
LEUKEMIA RESEARCH, 2022, 121 : S33 - S34
[2] Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667
Mauz-Koerholz, C.
Kelly, K. M.
Keller, F. G.
Ramchandren, R.
Nahar, A.
Giulino-Roth, L.
KLINISCHE PADIATRIE, 2020, 232 (02): : 83 - 83
[3] Phase II, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667
Mauz-Koerholz, C.
Kelly, K.
Keller, F.
Ramchandren, R.
Nahar, A.
Giulino-Roth, L.
ANNALS OF ONCOLOGY, 2019, 30
[4] KEYNOTE-667: Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy.
Mauz-Korholz, Christine
Kelly, Kara M.
Keller, Frank G.
Giulino-Roth, Lisa
Nahar, Akash
Balakumaran, Arun
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[5] PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH CLASSICAL HODGKIN LYMPHOMA (CHL) WITH SLOW EARLY RESPONSE (SER) TO FRONT-LINE CHEMOTHERAPY (KEYNOTE-667)
Vinti, Luciana
Daw, Stephen
Alvarez, Constantino Sabado
Fagioli, Franca
Beishuizen, Auke
Michel, Gerald
Moleti, Maria
Cepelova, Michaela
Thorwarth, Anne
Rigaud, Charlotte
De Sabando, Diego Plaza Lopez
Landman-Parker, Judith
Shen, Juan
Pillai, Pallavi
Marinello, Patricia
Mauz-Koerholz, Christine
PEDIATRIC BLOOD & CANCER, 2023, 70 : S29 - S30
[6] Efficacy and safety of pembrolizumab (pembro) in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo) in the phase 2, open-label, KEYNOTE-667 study
Vinti, Luciana
Daw, Stephen
Sabado Alvarez, Constantino
Fagioli, Franca
Beishuizen, Auke
Michel, Gerard
Luisa Moleti, Maria
Cepelova, Michaela
Thorwarth, Anne
Rigaud, Charlotte
Lopez de Sabando, Diego Plaza
Landman-Parker, Judith
Shen, Juan
Pillai, Pallavi
Marinello, Patricia
Mauz-Koerholz, Christine
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[7] Phase 2, open-label study of pembrolizumab in children and young adults with newlydiagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667.
Mauz-Korholz, Christine
Kelly, Kara M.
Keller, Frank G.
Ramchandren, Rod
Nahar, Akash
Giulino-Roth, Lisa
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[8] Pembrolizumab (pembro) in Children and Young Adults with Low-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Early Results from the Phase 2 Keynote-667 Study
Giulino, Lisa
Keller, Frank
Toledo, Mario Melgar
Castellino, Sharon M.
Forlenza, Christopher J.
Catalan, Maitane Andion
Krystal, Julie
Lamble, Adam
Rao, Aarati V.
Morales, Fabio Molina
Cooper, Stacy
Luisi, Flavio
Llano, Oscar Gonzalez
Lopez, Karla Alejandra
Mauz-Koerholz, Christine
Hoppe, Bradford
Shen, Juan
Pillai, Pallavi
Marinello, Patricia
Kelly, Kara M.
BLOOD, 2023, 142
[9] Pembrolizumab (pembro) in Children and Young Adults with High-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Updated Results from the Phase 2 Keynote-667 Study
Mauz-Koerholz, Christine
Beishuizen, Auke
Vinti, Luciana
Ceraulo, Antony
Michel, Gerard
Cepelova, Michaela
Fagioli, Franca
Alvarez, Constantino Sabado
Cepelova, Michaela
Fagioli, Franca
Alvarez, Constantino Sabado
Ducassou, Stephane
Buffardi, Salvatore
Catalan, Maitane Andion
Hoppe, Brad
Keller, Frank
Kelly, Kara M.
Roth, Lisa Giulino
Landman-Parker, Judith
Shen, Juan
Pillai, Pallavi
Daw, Stephen
BLOOD, 2023, 142
[10] Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study
Mauz-Koerholz, Christine
Vinti, Luciana
Daw, Stephen
Ceraulo, Antony
Michel, Gerard
Cepelova, Michaela
Valero-Arrese, Lorena
Fagioli, Franca
Ducassou, Stephane
Buffardi, Salvatore
Leblanc, Thierry
Hoppe, Bradford S.
Keller, Frank G.
Kelly, Kara M.
Roth, Lisa Giulino
Landman-Parker, Judith
Shen, Juan
Pillai, Pallavi
Yusuf, Rushdia
Beishuizen, Auke
BLOOD, 2024, 144 : 3055 - 3056

← 1 2 3 4 5 →